Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment

Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. In real-world practice, decr...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Song Y, Green, Austin R, Hadi, Rouba, Doolittle-Amieva, Coley, Gardner, Jennifer, Moshiri, Ata S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621191/
https://www.ncbi.nlm.nih.gov/pubmed/36307152
http://dx.doi.org/10.1136/jitc-2022-005257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621191/
https://www.ncbi.nlm.nih.gov/pubmed/36307152
http://dx.doi.org/10.1136/jitc-2022-005257

Ejemplares similares